| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.vistapharmaceuticals.com | |
| Market Cap | 39.21 Cr. | |
| Enterprise Value(EV) | 49.05 Cr. | 2023-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -1.47 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 33.57 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 9.17 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 1.08 | Calculated using Price: 9.91 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 3.96 Cr. | 39,570,203 Shares |
| FaceValue | 2 | |
| About Vista Pharmaceuticals Ltd. | ||
| Vista Pharmaceuticals Limited was incorporated on January 25,1991 under the Companies Act of 1956 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. Vista Pharmaceuticals was incorporated by Dr. Dhananjaya Alli & his associates. The capital was subscribed by Vista Pharmaceuticals Inc., an Overseas Corporate Body promoted by them as a per the laws of State of New Jersy, United States of America. | ||
| 1 Day |
|
-0.50% |
| 1 Week |
|
+12.61% |
| 1 Month |
|
+4.38% |
| 3 Month |
|
+19.33% |
| 6 Month |
|
+21.65% |
| 1 Year |
|
+21.95% |
| 2 Year |
|
-11.89% |
| 5 Year |
|
-73.92% |
| 10 Year |
|
+281.68% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 5.27 | 13.94 | 7.15 | 8.97 | 10.19 | 3.15 | -11.68 | -6.43 | -2.44 | |
| Return on Capital Employed (%) | 5.38 | 14.16 | 9.57 | 8.92 | 12.42 | 6.28 | -5.20 | -5.10 | -3.63 | |
| Return on Assets (%) | 3.27 | 7.39 | 3.15 | 3.70 | 4.67 | 1.78 | -7.11 | -3.89 | -1.59 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
| Shh. Funds | 9 | 10 | 11 | 17 | 32 | 36 | 30 | 33 | 35 | 37 | |
| Non Curr. Liab. | 0 | 0 | 8 | 5 | 6 | 6 | 5 | 11 | 6 | 4 | |
| Curr. Liab. | 5 | 12 | 7 | 19 | 15 | 11 | 16 | 9 | 11 | 15 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 14 | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 | 55 | |
| Non Curr. Assets | 12 | 11 | 10 | 16 | 25 | 29 | 30 | 37 | 37 | 34 | |
| Curr. Assets | 2 | 12 | 16 | 26 | 28 | 23 | 21 | 15 | 15 | 21 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 14 | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 | 55 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. TTM |
| Net Sales | 8 | 14 | 15 | 24 | 29 | 31 | 23 | 1 | 0 | 1 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | |
| Total Income | 8 | 14 | 15 | 24 | 29 | 34 | 27 | 1 | 1 | 1 | |
| Total Expenditure | -7 | -11 | -13 | -21 | -24 | -30 | -28 | -3 | -2 | -3 | |
| PBIDT | 1 | 3 | 3 | 3 | 6 | 4 | -1 | -2 | -1 | -2 | |
| Interest | 0 | -1 | -1 | -2 | -2 | -2 | -2 | -1 | -1 | ||
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | |
| Taxation | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 2 | 2 | -1 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 1 | 1 | 1 | 2 | 1 | -4 | -2 | -1 | -6 | |
| Adjusted EPS | 0 | 1 | 0 | 0 | 1 | 0 | -1 | -1 | 0 | -2 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | -4 | -3 | 3 | -5 | 3 | 1 | -7 | -1 | |
| Cash Fr. Inv. | 0 | 0 | 0 | 0 | -4 | -11 | -6 | -2 | 0 | 0 | |
| Cash Fr. Finan. | 0 | 4 | 3 | 6 | 11 | 1 | 0 | 7 | 1 | ||
| Net Change | 0 | 0 | 0 | 5 | -4 | -1 | -1 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 6 | 2 | 1 | 0 | 0 | 0 |
|
Fri, 09 Jun 2023
Announcement under Regulation 30 (LODR)-Allotment This is to inform the Exchange(s) that pursuant to the special resolution passed by the members of the Company under Section 62 of the Companies Act 2013 on 14th October 2022 and In- principle approval received from BSE on 30.11.2022 and the allotment of warrants dated 14th December 2022 the allotment of 6 96 870 equity shares of Rs.2/- in the Companys Equity Share Capital on conversion of 6 96 870 Warrants be and are hereby allotted to the person as mentioned below at a price of Rs.10/- per equity shares includes a premium of Rs.8/- per share: for which the Board of Directors have accorded their approval at their meeting held on 09th June 2023 Commenced at 03.00 P.M and Concluded at 03.30 P.M. Sl. No Name of the Allottee No of Equity Shares 1. Mr. Murali Marega (Managing Director) 4 96 8702. Mr. Pavan Sathvik Gilaka (Whole Time Director) 2 00 000 Total 6 96 870 |
|
Thu, 01 Jun 2023
Statement Of Deviation Or Variation In Utilization Of Funds Raised Through Preferential Issue Of Equity Shares Of The Company For The Quarter Ended On March 31St 2023. Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular CIR/CFD/CMD1/16212019 dated December 24 2019please find enclosed herewith the Statement of Deviation or Variation in utilization of funds raised through preferential issue of Equity Shares of the Company for the quarter ended on March 3lst 2023.Kindly take the same on record and acknowledge the receipt of the same. |
|
Tue, 30 May 2023
Compliances-Reg.24(A)-Annual Secretarial Compliance In compliance with Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 and SEBI Circular No. CIR/CFD/CMD/27/2019 dated February 8 2019 please find enclosed herewith copy of Annual Secretarial Compliance Report dated May 30 2023 for the Financial Year 2022-23 issued by our Secretarial Auditor N.V.S.S. Suryanarayana Practicing Company Secretary. |
| Fri, 09 Jun 2023 |
High Delivery Percentage
|
Close Above Last Week High
|
High Increase in 3 Months
|
High Increase in 6 Months
|
CCI Overbought Zone
|
Equities
M.F.
Sectors
StockEdge Social